Summary
This European multi-centre observational study examined the clinical outcomes of patients with advanced urothelial carcinoma treated sequentially with frontline and second-line anti-PD-1/PD-L1 checkpoint inhibitors. The analysis, as suggested by the large international author consortium and 2019 publication in a leading urology journal, characterised response durability and survival metrics to inform understanding of how successive immunotherapy lines perform in this patient population. The findings contribute to real-world evidence on checkpoint inhibitor sequencing strategies in advanced urothelial cancer.
UK applicability
The findings are applicable to UK urology and oncology practice, as anti-PD-1/PD-L1 checkpoint inhibitors are approved treatments for advanced urothelial cancer within the NHS. The observational data on sequential immunotherapy outcomes may inform treatment sequencing decisions in UK clinical practice, though results reflect European rather than UK-specific cohorts.
Key measures
Response rates, progression-free survival, overall survival, treatment sequencing patterns, clinical trajectory across immunotherapy lines
Outcomes reported
The study assessed clinical outcomes, including response rates, progression-free survival, and overall survival in patients with advanced urothelial cancer receiving sequential frontline and second-line anti-PD-1/PD-L1 checkpoint inhibitors. The analysis characterised outcome patterns and survival metrics as patients progressed through successive immunotherapy lines.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.